Scarica l'app Stockscreener
1.29
1.57%
0.02
Dopo l'orario di chiusura:
1.29
Panoramica
Notizia
Cronologia dei prezzi
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1.27
Aprire:
$1.26
Volume 24 ore:
116.80K
Relative Volume:
0.59
Capitalizzazione di mercato:
$3.19M
Reddito:
-
Utile/perdita netta:
$-15.08M
Rapporto P/E:
-0.2009
EPS:
-6.42
Flusso di cassa netto:
$-11.56M
1 W Prestazione:
+7.50%
1M Prestazione:
+0.00%
6M Prestazione:
-73.40%
1 anno Prestazione:
-88.97%
Intervallo 1D:
$1.23
$1.31
Intervallo di 1 settimana:
$1.16
$1.33
Portata 52W:
$1.01
$11.87
Enveric Biosciences Inc Stock (ENVB) Company Profile
Nome
Enveric Biosciences Inc
Settore
Industria
Telefono
239-302-1707
Indirizzo
4851 TAMIAMI TRAIL N, SUITE 200, NAPLES
Confronta ENVB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
1.29 | 2.97M | 0 | -15.08M | -11.56M | -6.42 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Enveric Biosciences Inc Borsa (ENVB) Ultime notizie
Enveric Receives U.S. Patent for Sleep, CNS Therapeutics - Insider Monkey
Enveric’s Patent Win Targets New Frontiers in Sleep Medicine - microdose.buzz
Enveric Biosciences Holds 2025 Annual Stockholders Meeting - TipRanks
Enveric Biosciences (ENVB) Secures Patent for Novel CNS Therapeu - GuruFocus
Enveric Biosciences Receives New US Patent on Molecules for Central Nervous System, Sleep Therapeutics - marketscreener.com
Enveric Biosciences secures patent for sleep disorder molecules By Investing.com - Investing.com Nigeria
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds | ENVB Stock News - GuruFocus
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds - Business Wire
Enveric Biosciences announces results from EB-003 trial - Yahoo Finance
Enveric’s EB-003 shows statistically significant improvements in model of severe chronic depression - BioWorld MedTech
Enveric Biosciences Reports Positive Preclinical Results For Lead Drug Candidate EB-003 - marketscreener.com
Enveric Biosciences reports breakthrough in depression model By Investing.com - Investing.com India
Enveric Biosciences (ENVB) Reports Promising Preclinical Results - GuruFocus
Enveric Biosciences reports breakthrough in depression model - Investing.com Australia
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 | ENVB Stock News - GuruFocus
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003 - Business Wire
Enveric Biosciences (NASDAQ:ENVB) Stock Price Down 0.8% – Here’s Why - Defense World
Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease - marketscreener.com
Enveric Biosciences Stakes Its Claim in Neurodegeneration Market - microdose.buzz
Enveric Biosciences files provisional patent for new molecules By Investing.com - Investing.com Canada
Enveric Biosciences Identifies Neuroplastogen Candidates with Po - GuruFocus
Enveric Biosciences (ENVB) Explores New Path with Neurodegenerative Drug Patent | ENVB Stock News - GuruFocus
Enveric Biosciences files new provisional patent application - TipRanks
Enveric Biosciences (ENVB) Explores New Path with Neurodegenerat - GuruFocus
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results - BioSpace
Enveric Biosciences Reports First Quarter 2025 Financial and Cor - GuruFocus
Enveric Biosciences (ENVB) Projected to Post Earnings on Tuesday - Defense World
Enveric Biosciences stock plummets after pricing $5M capital raise - MSN
Enveric Biosciences (NASDAQ:ENVB) Trading Down 1% – Here’s Why - Defense World
Enveric Biosciences appoints new accounting firm - Investing.com India
Enveric Biosciences appoints new accounting firm By Investing.com - Investing.com South Africa
ENVB Stock Touches 52-Week Low at $1.12 Amid Market Challenges - Investing.com Canada
ENVB Stock Touches 52-Week Low at $1.12 Amid Market Challenges By Investing.com - Investing.com South Africa
Psychedelic: Enveric, Filament Health report earnings results - TipRanks
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 - BioSpace
Enveric posts $9.5M loss for 2024, but revenue could be on horizon with licensing deals - Green Market Report
Enveric Lands Massive $184M Biotech Licensing Deals as EB-003 Shows Promise - Stock Titan
Enveric Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Enveric Biosciences, Inc. SEC 10-K Report - TradingView
Enveric Biosciences Inc. (ENVB) reports earnings - qz.com
Enveric Biosciences Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Enveric Biosciences Announces 1-for-15 Reverse Stock Split - MSN
Enveric Biosciences Participating in BIO-Europe Spring® - The Bakersfield Californian
Enveric Biosciences (ENVB) to Release Quarterly Earnings on Monday - Defense World
What is HC Wainwright’s Forecast for ENVB Q4 Earnings? - The AM Reporter
Q4 Earnings Forecast for ENVB Issued By HC Wainwright - Defense World
HC Wainwright Reiterates “Buy” Rating for Enveric Biosciences (NASDAQ:ENVB) - Defense World
Enveric Biosciences, Inc. (ENVB) Seeks Buyers for PsyAI Trademark Amid Shift to Neuroplastogen Development - Insider Monkey
Enveric Biosciences launches RFP solicitation process for PsyAI trademark - Yahoo Finance
Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark - 01Net
Enveric Biosciences Says Regains Compliance With Nasdaq Bid Price Rule -March 06, 2025 at 11:30 am EST - Marketscreener.com
Enveric Biosciences Inc Azioni (ENVB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):